EcoDrugPlus

Proteasome Subunit Alpha Type-6

Ensembl ID : ENSACLG00000023694
Gene Symbol: LOC113006871
3 Cross references
262 Possible Orthologues:

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSACLG00000024936
Gene Symbol: LOC113011828
3 Cross references
229 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSACLG00000020225
Gene Symbol: PSMB11
1 Cross references
170 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSACLG00000020616
Gene Symbol: LOC113010979
3 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-6-Like

Ensembl ID : ENSACLG00000008141
Gene Symbol: LOC113016206
3 Cross references
228 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSACLG00000015988
Gene Symbol: LOC113025271
3 Cross references
215 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSACLG00000019216
Gene Symbol: LOC113025283
3 Cross references
172 Possible Orthologues:

Proteasome Subunit Beta Type-9-Like

Ensembl ID : ENSACLG00000019881
Gene Symbol: LOC113015216
3 Cross references
209 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSACLG00000020188
Gene Symbol: PRMT5
1 Cross references
199 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSACLG00000026309
Gene Symbol: LOC113006343
3 Cross references
203 Possible Orthologues:

Protein Kinase C Alpha

Ensembl ID : ENSACLG00000002330
Gene Symbol: PRKCA
3 Cross references
212 Possible Orthologues:

Protein Kinase C Beta

Ensembl ID : ENSACLG00000010207
Gene Symbol: PRKCB
4 Cross references
213 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).